<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:Georgia;
panose-1:2 4 5 2 5 4 5 2 3 3;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:24.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
h2
{mso-style-priority:9;
mso-style-link:"Heading 2 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:18.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Cambria","serif";
color:#365F91;
font-weight:bold;}
span.Heading2Char
{mso-style-name:"Heading 2 Char";
mso-style-priority:9;
mso-style-link:"Heading 2";
font-family:"Cambria","serif";
color:#4F81BD;
font-weight:bold;}
span.EmailStyle20
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.EmailStyle21
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>See below for the reply from my radiation oncologist at PMCC wrt my question regarding the article on the new machine.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Helou, Joelle [<b>Sent:</b> October 3, 2018 9:25 AM<br><b>To:</b> Glen Tolhurst<br><b>Subject:</b> Re: 'More cures, fewer side-effects' with pioneering radiotherapy machine - BBC News<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>Both centres have MRlinac installed and will be up and running in the near future. <o:p></o:p></p><div><p class=MsoNormal>Best<o:p></o:p></p></div><div><p class=MsoNormal style='margin-bottom:12.0pt'>Joelle<o:p></o:p></p><div id=AppleMailSignature><p class=MsoNormal>Sent from my iPhone<o:p></o:p></p></div><div><p class=MsoNormal style='margin-bottom:12.0pt'><br>On Oct 3, 2018, at 9:00 AM, Glen Tolhurst <<a href="mailto:glen.tolhurst@sympatico.ca">glen.tolhurst@sympatico.ca</a>> wrote:<o:p></o:p></p></div><blockquote style='margin-top:5.0pt;margin-bottom:5.0pt'><div><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi Dr. Joelle Helou:</span><o:p></o:p></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Below is a very interesting article.</span><o:p></o:p></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Is there any such PCa treatment available in Canada, particularly @ PMCC or Sunnybrook?</span><o:p></o:p></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Thank you,</span><o:p></o:p></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen</span><o:p></o:p></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'> </span><o:p></o:p></p><p><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:blue'>Glen N. Tolhurst P.Eng. MBA</span></b><o:p></o:p></p><p><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:blue'>Chair PCCN Waterloo- Wellington</span></b><o:p></o:p></p><p><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'>web site: </span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:black'><a href="http://pccn-waterloo-wellington.ca/" id=LPlnk825412><span style='font-size:14.0pt;font-family:"Arial","sans-serif"'>http://pccn-waterloo-wellington.ca/</span></a></span><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'> </span><o:p></o:p></p><p><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'>e-mail: </span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:black'><a href="mailto:info@pccn-waterloo-wellington.ca"><span style='font-size:14.0pt;font-family:"Arial","sans-serif"'>info@pccn-waterloo-wellington.ca</span></a></span><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'> </span><o:p></o:p></p><p><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'>answering service 226-240-9264</span><o:p></o:p></p><p><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:red'>Direct contact via:</span><o:p></o:p></p><p><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'>Tel (519) 826-0716 </span><o:p></o:p></p><p><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'>Cell (519) 994-4536</span><o:p></o:p></p><p><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'>e-mail: </span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:black'><a href="mailto:Glen46Nor@gmail.com"><span style='font-size:14.0pt;font-family:"Arial","sans-serif"'>Glen46Nor@gmail.com</span></a></span><o:p></o:p></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'> </span><o:p></o:p></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'> </span><o:p></o:p></p><p class=MsoNormal> <o:p></o:p></p><div><p class=MsoNormal> <o:p></o:p></p></div><div><blockquote style='margin-top:5.0pt;margin-bottom:5.0pt;color:inherit;padding:inherit;margin:inherit'><div><div><p class=MsoNormal style='margin-bottom:12.0pt'><br><a href="https://www.bbc.com/news/health-45627165">https://www.bbc.com/news/health-45627165</a><o:p></o:p></p></div><div id=article><div><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;mso-line-height-alt:14.55pt'><span style='font-size:28.5pt;font-family:"Georgia","serif"'>'More cures, fewer side-effects' with pioneering radiotherapy machine</span><o:p></o:p></h1><div><p class=MsoNormal style='line-height:18.0pt'><span style='font-size:14.5pt;font-family:"Georgia","serif"'><p06m1xvz.jpg></span><o:p></o:p></p></div><p class=MsoNormal style='line-height:18.0pt'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>Barry Dolling is prepared for treatment in the MR Linac by therapeutic radiographers </span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt'><b><span style='font-size:14.5pt;font-family:"Georgia","serif"'>The first patient in the UK has been treated with a pioneering new radiotherapy machine. </span></b><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>The MR Linac simultaneously scans tumours inside the body while delivering X-ray radiation beams. </span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>It means clinicians can plan and adjust radiotherapy in real time, allowing it to be more accurate than ever before.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>The team at the<a href="https://www.icr.ac.uk/news-features/mr-linac"><span style='color:#416ED2'> Institute of Cancer Research</span></a> and the <a href="https://www.royalmarsden.nhs.uk/rm-magazine/mr-linac"><span style='color:#416ED2'>Royal Marsden Hospital</span></a> in London describe the technology as "groundbreaking".</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>They hope it will lead to more patients being cured while experiencing fewer side-effects.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>Barry Dolling, 65, who has <span style='background:yellow;mso-highlight:yellow'>prostate cancer</span>, is the first patient in the UK to be treated.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>He told me: "I feel privileged and excited to be part of this. I volunteered to be part of the <a href="https://clinicaltrials.gov/ct2/show/NCT03658525"><span style='color:#416ED2'>Prism</span></a> trial and feel my treatment and the research will help others diagnosed with prostate cancer in the future." </span><o:p></o:p></p><h2 style='mso-line-height-alt:18.0pt;max-width: 100%'><span style='font-size:20.5pt;font-family:"Georgia","serif"'>Pioneering</span><o:p></o:p></h2><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>Prof Uwe Oelfke, who leads the joint MR Linac project at the ICR and Marsden, told me: "Ten years ago we did not think it would be possible to combine MRI and radiotherapy - this is a real step-change in technology."</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>The machine has been specially designed so that the magnetic coils of the MRI and the X-ray beam of the linear accelerator do not interfere with each other.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>It will be especially useful in treating tumours that shift in size and shape in the body, such as in the lung, bladder and bowel.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>Dr Alison Tree, consultant oncologist at the Royal Marsden, described the new technology as "a dream come true" that would enable clinicians to deliver more targeted, higher doses of radiation, sparing healthy tissue.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>"In lung cancer, we would like to give higher doses of radiotherapy but are limited because the tumour is often close to other vital structures in the chest," she said.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>"This allows us to see the cancer more clearly and make sure the radiation goes where it is needed and not where it can cause harm."</span><o:p></o:p></p><h2 style='mso-line-height-alt:18.0pt;max-width: 100%'><span style='font-size:20.5pt;font-family:"Georgia","serif"'>Single treatment </span><o:p></o:p></h2><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>The ability to give higher doses of radiation will enable patients to complete their treatment more quickly.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>Mr Dolling will have 20 sessions of radiotherapy in the MR Linac. But it's predicted that eventually it will be possible to cure some cancers in a single treatment.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>The Royal Marsden will treat prostate, rectal, bowel, bladder, cervical and eventually lung cancer in the MR Linac.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>The installation of the MR Linac was made possible by a £10m grant from the Medical Research Council, plus support from <a href="https://www.royalmarsden.org/"><span style='color:#416ED2'>the Royal Marsden Cancer Charity</span></a>.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>A second machine, at the Christie in Manchester, will begin treating patients early next year.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>Both hospitals are part of an international research consortium together with companies <a href="https://mrrt.elekta.com/?utm_source=mr-linac&utm_medium=redirect&utm_campaign=redirects"><span style='color:#416ED2'>Elekta, </span></a>which makes the MR Linac, and Phillips.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>So far, the only other cancer centres to treat patients with the MR Linac are in the Netherlands, in Utrecht and Amsterdam.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>The prospect of more accurately targeted radiotherapy, with fewer side-effects, will inevitably mean there will be high demand for access to treatment in the MR Linac.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>Dr Tree said there would be several clinical trials and priority would be given to research that yielded the most benefit to patients.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>There have been significant improvements in radiotherapy treatment in recent years - it already contributes to 40% of all the cases of cancer that are cured.</span><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:18.0pt;max-width: 100%'><span style='font-size:14.5pt;font-family:"Georgia","serif"'>Follow Fergus on <a href="https://twitter.com/BBCFergusWalsh"><span style='color:#416ED2'>Twitter.</span></a></span><o:p></o:p></p></div></div></div></blockquote></div></div></blockquote></div><p class=MsoNormal><br>This e-mail may contain confidential and/or privileged information for the sole use of the intended recipient. <br>Any review or distribution by anyone other than the person for whom it was originally intended is strictly prohibited. <br>If you have received this e-mail in error, please contact the sender and delete all copies. <br>Opinions, conclusions or other information contained in this e-mail may not be that of the organization. <br><br>If you feel you have received an email from UHN of a commercial nature and would like to be removed from the sender's mailing list please do one of the following: <br>(1) Follow any unsubscribe process the sender has included in their email <br>(2) Where no unsubscribe process has been included, reply to the sender and type "unsubscribe" in the subject line. If you require additional information please go to our UHN Newsletters and Mailing Lists page. <br>Please note that we are unable to automatically unsubscribe individuals from all UHN mailing lists.<o:p></o:p></p></div></body></html>